GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BetterLife Pharma Inc (STU:NPAU) » Definitions » Total Payout Ratio

BetterLife Pharma (STU:NPAU) Total Payout Ratio : 0.75 (As of Jun. 01, 2024)


View and export this data going back to 2018. Start your Free Trial

What is BetterLife Pharma Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

BetterLife Pharma's current Total Payout Ratio is 0.75.


BetterLife Pharma Total Payout Ratio Historical Data

The historical data trend for BetterLife Pharma's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BetterLife Pharma Total Payout Ratio Chart

BetterLife Pharma Annual Data
Trend Jan14 Jan15 Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 0.83 0.04 0.94 0.09

BetterLife Pharma Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 1.65 0.22 1.34

Competitive Comparison of BetterLife Pharma's Total Payout Ratio

For the Biotechnology subindustry, BetterLife Pharma's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BetterLife Pharma's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BetterLife Pharma's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where BetterLife Pharma's Total Payout Ratio falls into.



BetterLife Pharma Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

BetterLife Pharma's Total Payout Ratio for the fiscal year that ended in Jan. 2023 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0.576 + 0) / -6.481
=0.09

BetterLife Pharma's Total Payout Ratio for the quarter that ended in Oct. 2023 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0.198 + 0) / -0.148
=1.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BetterLife Pharma Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of BetterLife Pharma's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BetterLife Pharma (STU:NPAU) Business Description

Traded in Other Exchanges
Address
1275 West 6th Avenue, Suite 300, Vancouver, BC, CAN, V6H 1A6
BetterLife Pharma Inc a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumors to treat various types of cancer.

BetterLife Pharma (STU:NPAU) Headlines

No Headlines